3. Other information required by law
3.1 Name, legal form and registered office
BB Biotech AG is a limited company according to the Swiss Code of Obligation and has its registered office at Schwertstrasse 6 in Schaffhausen.
3.2 Declaration of number of full-time equivalents
The number of full-time equivalents did not exceed 10 in the calendar year 2020 (2019: below 10).
3.3 Investments
Investments of BB Biotech AG comprise, in the business years 2020 and 2019, the following subsidiaries:
|
Company |
|
Capital in CHF 1 000 |
|
Capital and voting interest in % |
|
Biotech Focus N.V., Curaçao |
|
11 |
|
100 |
|
Biotech Growth N.V., Curaçao |
|
11 |
|
100 |
|
Biotech Invest N.V., Curaçao |
|
11 |
|
100 |
|
Biotech Target N.V., Curaçao |
|
11 |
|
100 |
3.4 Treasury shares (balances and change)
Treasury shares are partly held by the Company directly and partly by its 100% subsidiary Biotech Target N.V. indirectly.
|
|
|
BB Biotech AG |
|
Biotech Target N.V. |
|
Total |
|
Balance at January 1, 2019 |
|
– |
|
– |
|
– |
|
Balance at December 31, 2019 |
|
– |
|
– |
|
– |
|
|
|
|
|
|
|
|
|
Purchases Biotech Target N.V. at an average price of CHF 71.83 |
|
– |
|
114 998 |
|
114 998 |
|
Sales Biotech Target N.V. at an average price of CHF 60.18 |
|
– |
|
(336) |
|
(336) |
|
Balance at December 31, 2020 |
|
– |
|
114 662 |
|
114 662 |
3.5 Audit fees
The audit fees comprise the following (in CHF):
|
|
|
2020 |
|
2019 |
|
Audit fees |
|
120 000 |
|
120 000 |
|
Audit-related fees |
|
2 800 |
|
2 000 |
|
|
|
122 800 |
|
122 000 |
3.6 Commitments and contingencies
The Company had no commitments or other off-balance sheet transactions open at December 31, 2020 (2019: none).
The operations of the Company are affected by legislative, fiscal and regulatory developments for which provisions are made where deemed necessary. The Board of Directors concludes that as at December 31, 2020, no proceedings existed which could have any material effect on the financial position of the Company (2019: none).
3.7 Subsequent events
There have been no events subsequent to December 31, 2020, which would affect the 2020 financial statements.